La lipoprotéine Lp(a):son intérêt dans l'interprétation du bilan lipidique

J. Intern. Med. 1992, 232, 349-352

352 PEDRO-BOTET J., SENTI M., AUGET T., NOGUES X., RUBIES-PRAT J. et al

Apolipoprotein(a) genetic polymorphism and serum lipoprotein(a) concentration in patients with peripheralvascular disease.

Atheroscler. 1993, 104, 87-94

353 PRIOR M., AROSIO E., FERRARI M., LUCCHESE L., GUIDI G. et al.

Lipoprotein(a) and general risk factors in patients with angiographically assessed peripheral arterial disease.

Int. Angiol. 1995, 14, 357-363

354 SUTTON-TYRRELL K., EVANS R.W., MEILAHN E., ALCORN H.G. Lipoprotein(a) and peripheral atherosclerosis in older adults.

Atheroscler. 1996, 122, 11-19

355 BRUCKERT E., DAVIDOFF P., GRIMALDI A., TRUFFERT J., GIRAL P. et al

Increased serum levels of lipoprotein(a) in diabetes mellitus and their reduction with glycemic control. JAMA 1990, 263, 35-36

356 JOVEN J., VILELLA E.

Serum levels of lipoprotein(a) in patients with well-controlled non-insulin-dependent diabetes mellitus. JAMA 1991, 265, 1113-1114

357 GUILLAUSSEAU P-J., PEYNET J., CHANSON P., LEGRAND A., ALTMAN J-J. et al Lipoprotein(a) in diabetic patients with and without chronic renal failure.

Daibetes Care 1992, 13, 976-979

358 HELLER F., JAMART J., HONORE P., DERUE G., NOVIK V. et al Serum lipoprotein(a) in patients with diabetes mellitus.

Diabetes Care 1993, 16, 819-823

359 SALZER B., STAVLJENIC A., JURGENS G., DUMIC M., RADICA A.

Polymorphism of apolipoprotein E, lipoprotein(a), and other lipoproteins in children with type I diabetes.

Clin. Chem. 1993, 39, 1427-1432

360 JENKINS A., STEELE J., JANUS E., BEST J.

Increased plasma apolipoprotein(a) levels in IDDM patients with microalbuminuria. Diabetes 1991, 40, 787-790

Thèse Docteur Pharmacie La lipoprotéine Lp(a) : son intérêt dans l'interprétation du bilan lipidique Dr GUIMONT MC 267/271 Lipides, Lipoprotéine (a), Hyperlipoprotéinémie, Athérosclérose, Lipids, Lipoprotein, Lpa, Hyperlipoproteinemia, Atherosclerosis

361 LEGRELLE M., BAUDUCEAU B., BOILLOT J., LE GUYADEC T., MAYAUDON H. et al. Lipoproteine(a) et facteurs de risque cardio-vasculaire. Etude d'une population de 131 diabétiques. Sem. Hôp. Paris 1994, 70, 191-197

362 CSASZAR A., DIEPLINGER H., SANDHOLZER C., KARADI I., JUHASZ E. et al Plasma lipoprotein(a) concentration and phenotypes in diabetes mellitus.

Diabetologica 1993, 36, 47-51

363 TAUPIN J-M., DURLACH V., HASSAIM M., GILLERY P., JOLLY D. et al. Lipoproteine(a) et diabète: relations à propos de 224 observations.

Diabète et Metabolisme 1993, 19, 250-256

364 HAFFNER S., TUTTLE K., RAINWATER D.

Decrease of lipoprotein(a) with improved glycemic control in IDDM subjects. Diabetes Care 1991, 14, 302-307

366 HAFFNER S., TUTTLE K., RAINWATER D.

Lack of change of lipoprotein(a) concentration with improved glycemic control in subjects with type II diabetes.

Metabolism 1992, 41, 116-120

366 BOEMI M., SIROLLA C., AMADIO L., FUMELLI P., JAMES R.W. Lipoprotein(a) and retinopathy in IDDM and NIDDM patients. Diabetes Care 1997, 20, 115

367 KARADI I., ROMICS L., PALOS G., DOMAN J., KASZAS I. et al

Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin. Clin. Chem. 1989, 35, 2121-2123

368 MASER R., USHER D., BECKER D., DRASH A., KULLER L. et al

Lipoprotein(a) concentration shows little relationship to IDDM complications in the Pittsburgh Epidemiology of Diabetes Complications Study Cohort.

Diabetes Care 1993, 16, 755-758

369 HAFFNER S., MOSS S., KLEIN B., KLEIN R.

Lack of association between lipoprotein(a) concentrations and coronary heart disease mortality in diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy.

Metabolism 1992, 41, 194-197

378 LYONS T.J., JENKINS A.J.

Lipoprotein glycation and its metabolic consequences Curr. Op. Lipidol. 1997, 8, 174-180

³⁷¹ PARRA H., MEZDOUR H., FRUCHART J-C., CACHERA C., DRACA M. et al. Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin. Chem. 1987, 33, 721 (Letter).

372 ORDONEZ J.D., HIATT R.A., KILLEBREW E.J., FIREMAN B.H.

The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int. 1993, 44, 638-642.

373 JOVEN

Accumulation of atherogenic remnants and Lp(a) in the nephrotic syndrome. Relation to remission of proteinuria.

Clin. Chem. 1995, 41, 908-913

374 STENVINKEL P., BERGLUND L., HEIMBURGER O., PETTERSSON E., ALVERSTRAND A. Lipoprotein(a) in nephrotic syndrome.

Kidney Int. 1993, 44, 1116-1123

Thèse Docteur Pharmacie La lipoprotéine Lp(a) : son intérêt dans l'interprétation du bilan lipidique Dr GUIMONT MC 268/271 Lipides, Lipoprotéine (a), Hyperlipoprotéinémie, Athérosclérose, Lipids, Lipoprotein, Lpa, Hyperlipoproteinemia, Atherosclerosis

375 APPEL G.B., BLUM C.B., CHIEN S., KUNIS C.L., APPEL A.S. The hyperlipidemia of the nephrotic syndrome.

N. Eng. J. Med. 1985, 312, 1544-1548

376 WANNER C., RADER D., BARTENS W., KRAMER J., BREWER H.B. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann. Int. Med. 1993, 119, 263-269

³⁷⁷ OIDA K., TAKAI H., MAEDA H., TAKAHASHI S., SHIMADA A. et al

Apolipoprotein(a) is present in urine and its excretion is decreased in patients with rénal failure. Clin. Chem. 1992, 38, 2244-2248

378 IRISH A., SIMONS L., SAVDIE E., HAYES J., SIMONS J.

Lipoprotein(a) levels in chronic renal disease states, dialysis and transplantation. Aust. N.Z. J. Med. 1992, 22, 243-248

³⁷⁹ GAULT M., LONGERICH L., PURCHASE L., HARNETT J., BRECKENRIDGE C. Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the litterature.

Nephron 1995, 70, 155-170

38° AUGUET T., SENTI M., RUBIES-PRAT J. PELEGRI A., PEDRO-BOTET J. et al

Serum lipoprotein(a) concentration in patients with chronic renal failure receiving haemodialysis: influence of apolipoprotein(a) genetic polymorphism.

Nephrol. Dial. Transplant. 1993, 8, 1099-1103

381 DIEPLINGER H., LACKNER C., KRONENBERG F., SANDHOLZER C., LHOTTA K.

Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to size polymorphism of apolipoprotein(a).